Penthrox is a SCHEDULE 4 drug in Australia. To purchase this product you are required to be a registered Health Care Professional with AHPRA. Additional conditions may apply. For further information contact 1800 PENTHROX(1800 736 847) MINIMUM PRODUCT INFORMATION Penthrox (methoxyflurane) Inhalation. Before prescribing, please review Approved Product Information. Full PI available from Medical Developments International Limited.
INDICATIONS: For emergency relief of pain by self administration in conscious haemodynamically stable patients with trauma and associated pain, under supervision of personnel trained in its use and for the relief of pain in monitored conscious patients who require alalgesia for surgical procedures such as the change of dressings.
CONTRAINDICATIONS: Use as an anaesthetic agent renal impairment renal failure hypersensitivity to fluorinated anaesthetics(including family history of hypersensitivity) cardiovascular instability respiratory depression head injury or loss of consciousness malignant hyperthermia.
PRECAUTIONS: Not to be used as an anaesthetic agent liver disease and liver damage after previous methoxyflurane or halothane anaesthesia diabetic patients (may have increased likelihood of developing nephropathy) daily use of methoxyflurane is not recommended treatment with enzyme inducing drugs (eg barbiturates) cautious use of adrenaline or nor-adrenaline during methoxyflurane administration caution in hot climates (do not expose to temperatures above 40 deg C, especially when used in conjunction with oxygen) use in pregnancy , the elderly and regular exposure to health workers.
INTERACTIONS: Antibiotics including tetracyclin, gentamicin, gentamicin, kanamycin, kanamycin, colistin, polymyxin B, cephaloridine and amphotericin B subsequent narcotics administration -blockers.
SIDE EFFECTS: With alalgesic doses - euphoria,drowsiness, sleepiness, agitation, restlessness, headache, dizziness, dissocation, amnesia, cough,chocking, hypotension, nausea, vomiting, hepatitis, increased liver enzymes, increased serum uric acid, urea nitrogen and creatinine, blurred vision, diplopia and nystagmus. Hepatic toxicity in association with methoxyflurane is rare.
DOSAGE AND ADMINISTRATION: Up to 6ml per day, vaporised in a PENTHROX Inhaler. The total weekly dose should not exceed 15ml. Administration on consecutive days is not recommended.
